Comprehensive Topicals CDMO MedPharm delivers end-to-end topical and transdermal development and manufacturing, spanning formulation, preclinical research, clinical trial supply, and commercial manufacturing. This makes them a strong partner for biotech and pharma seeking to de-risk development, accelerate timelines, and ensure regulatory alignment. Ideal opportunities include offering integrated development-to-commercial packages to dermatology, transdermal, and cosmetic-pharma programs, with emphasis on IND/CTA readiness and scalable supply planning.

Scale and Capabilities The 2024 merger with Tergus Pharma positions MedPharm as a scaled CDMO capable of large-batch manufacturing and distribution in addition to early development. This creates sales opportunities with midsize to large programs needing end-to-end services under one partner, bundled development through commercial manufacturing and distribution, and a single point of accountability for supply chain continuity.

Leadership Growth Signals Recent leadership changes including the appointment of a new CEO and board expansion signal an intention to grow and pursue strategic partnerships. This can be an opening to engage corporate development teams at biotech and pharma companies seeking scalable, strategically driven CDMO partnerships aligned with aggressive late-stage and commercial programs.

Niche Therapy Collaboration MedPharm's collaboration with Mosanna Therapeutics AG on Metabolic Obstructive Sleep Apnea demonstrates capability to support specialized, indication-specific programs. Approach: prioritize metabolic, sleep-disorder, and dermatology-focused startups seeking topical or transdermal solutions, and discuss co-development or clinical-supply arrangements that leverage MedPharm's regulatory expertise and end-to-end services.

Regional and Market Position Based in Durham, NC with 201-500 employees and mid-market revenue, MedPharm sits in a growing biotech corridor with local access to talent, suppliers, and regulatory talent. Position as a flexible, customer-centric alternative to larger CDMOs for niche topical programs, while offering scale, reliability, and domestic supply for U.S. and North American customers.